A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 7, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

June 30, 2026

Conditions
Higher-risk Myelodysplastic Syndromes
Interventions
DRUG

AK117

AK117 IV injection

DRUG

Placebo

Placebo IV injection

DRUG

Azacitidine

Azacitidine SC injection

Trial Locations (15)

10467

RECRUITING

Montefiore Einstein Comprehensive Cancer Center, The Bronx

20817

RECRUITING

American Oncology Partners, PA (The Center for Cancer and Blood Disorders-Bethesda), Bethesda

21044

RECRUITING

Maryland Oncology-Columbia, Columbia

27514

RECRUITING

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

29425

RECRUITING

MUSC Hollings Cancer Center, Charleston

32763

RECRUITING

Mid Florida Hematology and Oncology Center, Orange City

43210

RECRUITING

Ohio State University, Columbus

44718

RECRUITING

Gabrail Cancer Center, Canton

63110

RECRUITING

Washington University School of Medicine in St. Louis, St Louis

80012

RECRUITING

Rocky Mountain Cancer Centers, Aurora

90095

RECRUITING

UCLA Ronald Reagan Medical Center, Los Angeles

97401

RECRUITING

Oncology Associates of Oregon, Eugene

06510

RECRUITING

Yale Cancer Center, New Haven

75390-9065

RECRUITING

UT Southwestern Medical Center, Dallas

Unknown

RECRUITING

Institute of hematolongy&blood diseases hospital, chinese academy of medical sciences&peking union medical college, Tianjin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Akeso

INDUSTRY